EMAIL THIS PAGE TO A FRIEND

Advances in oto-rhino-laryngology

Clinical experience with caroverine in inner ear diseases.


PMID 11885656

Abstract

The glutamatergic synapses between the cochlear inner hair cells and their afferent neurons seem to be mostly involved in the pathophysiology of the cochlea. Glutamatergic neurotoxicity is characterized by a mitochondrial overproduction of free oxygen radicals damaging lipid membranes and DNA structures of the postsynaptic neuron followed by the clinical symptoms of hearing loss and tinnitus. In preclinical tests, quinoxaline derivatives antagonized these deleterious consequences of too high an amount of free radicals. Therefore the clinically available quinoxaline dione caroverine provides a new approach to a successful treatment of tinnitus, sudden hearing loss and speech discrimination disorders in presbyacusis. The results of corresponding clinical trials are presented.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C1119
Caroverine hydrochloride, ≥98% (HPLC), solid
C22H28ClN3O2